Extended Data Fig. 8: Brain-resident leukocyte composition does not change with aging or conditional deletion of Vcam1.

a, Mouse model and experimental groups. n = 5 young Cre^– mice, 9 aged Cre^– mice, 4 ‘Vcam1-LT’ mice and 4 Vcam1-ST mice. Cre^– and Cre⁺ mice were used. The tamoxifen treatment paradigm is described in the schematic. b, Gating plots of CD31⁺VCAM1⁺ hippocampal and cortex cells isolated from one LPS-stimulated aged (19-month-old) Cre⁺ (Vcam1 deletion short term) mouse and one Cre^– mouse injected with anti-VCAM1-DL488 (r.o.) 2 h before killing to confirm VCAM1 levels on BECs were reduced. One additional Cre^– mouse was treated with LPS and injected with IgG-DL488 isotype control before killing to serve as a control for VCAM1 gating. c–j, Quantification of various cell populations present in young Cre^– (n = 5), aged Cre^– (n = 9), aged Vcam1-LT (n = 4) and aged Vcam1-ST (n = 4) mice per group. Data are shown as the mean ± s.e.m. *P = 0.0413, **P = 0.0245, ***P = 0.0429, ****P = 0.0023, one-way ANOVA with Tukey’s multiple-comparisons post hoc test.